Akeso Biopharma has presented updated Phase II data for its PD-1×CTLA-4 bispecific antibody (BsAb), cadonilimab, in combination with chemotherapy for the first-line treatment of advanced pancreatic ductal adenocarcinoma (PDAC). The data showed promising survival outcomes. In the overall study population, the median overall survival (mOS) was 13.8 months. The results were particularly strong in patients with locally advanced disease, who achieved a median progression-free survival (mPFS) of 11.1 months, a mOS exceeding 23 months, and a 12-month survival rate of 90%.

The combination demonstrated a disease control rate (DCR) of 96.4% and an objective response rate (ORR) of 33.9%, with most patients achieving tumour control. The safety profile was favourable, with no new safety signals identified. The data support the continued development of cadonilimab in this aggressive cancer with high unmet need.

According to PharmCube's NextBiopharm® database, cadonilimab is the only PD-1×CTLA-4 therapy under active development in PDAC. Click here to request a free trial for NextBiopharm®.